Akeso company information, Employees & Contact Information

Akeso’s Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML) 康方生物

A little-known Chinese company made a drug that beat the world’s biggest-selling medicine CNN

Akeso cracks the US at last | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

WSJ | Her Unusual Path to CEO and Finding a Cancer Drug 康方生物

Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck Bloomberg

Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax BioPharma Dive

Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial Fierce Pharma

Strong Phase III results for Akeso’s ivonescimab The Pharma Letter

Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US rivalry South China Morning Post

Summit, Akeso Lung Cancer Drug Rivals Merck’s Keytruda - Summit Therapeutics (NASDAQ:SMMT) Benzinga

Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype Fierce Pharma

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet 康方生物

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer 康方生物

Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC 康方生物

Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine 康方生物

Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer 康方生物

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF) 康方生物

Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China 康方生物

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap 康方生物

Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor 康方生物

Phase 1a/1b Study Results of Akeso’s PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy 康方生物

Akeso Occupational Health Opens its 21st Clinic in Los Angeles, CA Business Wire

New PD-1 Monoclonal Antibody 安尼可® (Penpulimab) Officially for Sale, First Prescriptions Made Nationwide 康方生物

Akeso and Summit notch another Phase III win with their Keytruda competitor Clinical Trials Arena

ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC Fierce Pharma

Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda statnews.com

Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®) 康方生物

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China 康方生物

Akeso Dr. Xia Yu and Dr. Wang Zhongmin Win the First “World-Benefiting Pharmaceutical Innovation” Award 康方生物

Akeso, Summit's PD-1xVEGF drug meets overall survival goal for the first time in a lung cancer trial Fierce Pharma

Akeso’s PD-1/CTLA-4 Bi-Specific Antibody Obtained Approval from the CDE to Submit NDA and has been Granted Priority Review Designation 康方生物

Akeso Completes the Acquisition of Immediate Medical Center, Adding Four Los Angeles-Based Clinics to Its Rapidly Growing Occupational Health Network and Expanding to a Total of 20 Clinics Statewide Business Wire

Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector BioSpace

The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions statnews.com

Akeso among “TOP 10 Chinese Bispecific Antibody Drug Companies” Ranked by BioChina List of China Biopharmaceuticals 康方生物

Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner Bloomberg

Akeso was included in the “Chinese Antibody Drug Companies Innovation TOP 30” by “2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists” 康方生物

Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback South China Morning Post

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer Fierce Pharma

Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think? Fierce Pharma

Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal Fierce Pharma

Fierce Pharma Asia—Akeso, Summit's Keytruda-beating data; BIOSECURE's House passage; Candid's $370M debut Fierce Pharma

Summit, Akeso's antibody triumphs over Keytruda in China lung cancer trial, sending shares skyrocketing Fierce Pharma

Summit bets $5B that Akeso's bispecific antibody will ascend clinical peaks in cancer Fierce Biotech

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104 simplywall.st

Akeso banks on pharma tie-up for growth after record-setting biotech IPO South China Morning Post

Chinese company's drug beats world's biggest-selling medicine: media China Daily

Wellness Wednesday: This is how you can use anger to fuel your drive glamour.co.za

Akeso opens an outpatient addiction facility in George George Herald

Akeso George helps fight teen suicide George Herald

Netcare gets competition clearance for R1.3bn Akeso takeover Moneyweb

Akeso officially opens its doors to assist all patients seeking aide The Citizen